Complete financial analysis of Schrödinger, Inc. (SDGR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Schrödinger, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Elopak ASA (ELO.OL) Income Statement Analysis – Financial Results
- GFH Financial Group BSC (GFH.AE) Income Statement Analysis – Financial Results
- Advenica AB (publ) (ADVE.ST) Income Statement Analysis – Financial Results
- Megaforce Company Limited (3294.TWO) Income Statement Analysis – Financial Results
- George Weston Limited (WNGRF) Income Statement Analysis – Financial Results
Schrödinger, Inc. (SDGR)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.schrodinger.com
About Schrödinger, Inc.
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 216.67M | 180.96M | 137.93M | 108.10M | 85.54M | 66.64M | 55.69M |
| Cost of Revenue | 75.97M | 79.93M | 72.31M | 44.62M | 36.45M | 23.70M | 15.89M |
| Gross Profit | 140.69M | 101.02M | 65.62M | 63.47M | 49.09M | 42.94M | 39.80M |
| Gross Profit Ratio | 64.93% | 55.83% | 47.57% | 58.72% | 57.39% | 64.43% | 71.46% |
| Research & Development | 181.77M | 126.37M | 90.90M | 64.70M | 39.40M | 34.52M | 27.67M |
| General & Administrative | 99.15M | 90.83M | 64.01M | 41.90M | 27.04M | 18.55M | 14.44M |
| Selling & Marketing | 37.23M | 30.64M | 22.15M | 17.80M | 21.36M | 17.83M | 16.72M |
| SG&A | 136.37M | 121.47M | 86.16M | 59.69M | 48.40M | 36.38M | 31.15M |
| Other Expenses | 0.00 | 3.95M | 1.06M | 2.25M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 318.14M | 247.84M | 177.06M | 124.39M | 87.81M | 70.91M | 58.82M |
| Cost & Expenses | 394.11M | 327.77M | 249.37M | 169.01M | 124.26M | 94.61M | 74.71M |
| Interest Income | 0.00 | 3.95M | 1.06M | 2.25M | 1.88M | 433.00K | 359.00K |
| Interest Expense | 0.00 | 3.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.55M | 4.34M | 2.85M | 3.66M | 3.64M | 2.89M | 1.69M |
| EBITDA | -171.90M | -142.47M | -108.60M | -57.26M | -35.08M | -25.08M | -17.34M |
| EBITDA Ratio | -79.34% | -80.01% | -86.97% | -79.12% | -52.60% | -36.41% | -28.18% |
| Operating Income | -177.45M | -149.12M | -111.44M | -60.92M | -38.72M | -27.97M | -19.02M |
| Operating Income Ratio | -81.90% | -82.41% | -80.80% | -56.35% | -45.26% | -41.97% | -34.15% |
| Total Other Income/Expenses | 220.37M | -2.31M | 10.64M | 34.62M | 12.74M | -379.00K | 1.96M |
| Income Before Tax | 42.92M | -149.13M | -100.81M | -26.29M | -25.97M | -28.35M | -17.06M |
| Income Before Tax Ratio | 19.81% | -82.41% | -73.09% | -24.32% | -30.36% | -42.54% | -30.63% |
| Income Tax Expense | 2.20M | 63.00K | 411.00K | 345.00K | -291.00K | 77.00K | 332.00K |
| Net Income | 40.72M | -149.19M | -101.22M | -26.64M | -25.68M | -28.43M | -17.39M |
| Net Income Ratio | 18.79% | -82.45% | -73.38% | -24.64% | -30.02% | -42.66% | -31.23% |
| EPS | 0.57 | -2.10 | -1.43 | -0.44 | -0.41 | -0.59 | -0.43 |
| EPS Diluted | 0.54 | -2.10 | -1.43 | -0.44 | -0.41 | -0.59 | -0.43 |
| Weighted Avg Shares Out | 71.78M | 71.17M | 70.59M | 60.02M | 63.27M | 48.47M | 40.38M |
| Weighted Avg Shares Out (Dil) | 74.99M | 71.17M | 70.59M | 60.02M | 63.27M | 48.47M | 40.38M |
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on August 9, 2023, the company granted (i) a non-statutory stock option to purchase 90,000 shares of the...
3 AI Stocks Billionaires Are Loading Up On
Many investors, including a significant number of very wealthy individuals and institutions, are becoming enthralled with AI stocks. According to Goldman Sachs (NYSE: GS ), up to $200 billion could be poured into the technology by 2025.
Why Shares of Schrödinger Are Falling Thursday
Second-quarter revenue was down 9% year over year. Schrödinger increased revenue guidance for software revenue but decreased it for drug discovery.
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.62 per share a year ago.
Schrödinger, Inc. (SDGR) Q2 2023 Earnings Call Transcript
Schrödinger, Inc. (NASDAQ:SDGR ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Jaren Madden - SVP, IR & Corporate Affairs Ramy Farid - CEO Geoff Porges - CFO Karen Akinsanya - President R&D, Therapeutics Conference...
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users.
Biotech & Healthcare Meet AI: Stocks Soar On Innovation Potential
But some stocks in the biotech category are rising for a reason that's more common with techs, such as chipmaker Nvidia Corp. NASDAQ: NVDA or Microsoft Corp. NASDAQ: MSFT, which has made a significant investment in OpenAI, developer of ChatGPT.
3 Cutting-Edge Biotech Stocks That Are Riding the AI Wave Like None Other
Recursion Pharmaceuticals just got Nvidia on board with its vision of AI for R&D. Ginkgo Bioworks is pairing AI with laboratory robotics to streamline R&D, too.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on July 14, 2023, the company granted (i) non-statutory stock options to purchase 10,250 shares of the company's...
Schrödinger to Announce Second Quarter 2023 Financial Results on August 2
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its second quarter 2023 financial results on Wednesday, August 2, 2023, after the financial markets close. The company will host...
Source: https://incomestatements.info
Category: Stock Reports